CellectisのEBIT margin
CellectisのEBIT marginは何ですか。
CellectisのEBIT marginは-458.76%です。
EBIT marginの定義は何ですか。
EBIT margin is a profitability ratio that measures earnings of the company as a percentage of revenue without taking into account the effect of taxes and interest.
ttm (trailing twelve months)
EBIT margin measures the profitability and operational efficiency of a company. It compares the amount of money that remains after the cost of goods and all operating expenses are subtracted from net revenue to sales. EBIT margin is calculated as earnings before interest and taxes divided by net revenue.
EBIT and EBIT margin evaluate how well a business manages its operations. Interest and taxes are not operating expenses and don’t impact operating efficiency. EBIT margin is usually used to compare operational efficiency and profitability of companies within the same industry. Taxes can vary by location thus excluding them from the calculation gives a better basis for comparing different companies.
EBIT and operating income are often used interchangeably, but there is a difference between them, which can cause the numbers to give different results. The key difference is that operating income does not include non-operating income, non-operating expenses, and other income.
NASDAQのセクタHealth CareにおけるEBIT marginの企業と比べるCellectis
Cellectisは何をしますか。
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Cellectisと類似のebit margin
- Bionano GenomicsのEBIT marginは-469.13%です。
- Delcath SystemsのEBIT marginは-468.64%です。
- Curis IncのEBIT marginは-468.18%です。
- Aquarius AIのEBIT marginは-467.83%です。
- Spruce BiosciencesのEBIT marginは-467.49%です。
- SenesTech IncのEBIT marginは-463.24%です。
- CellectisのEBIT marginは-458.76%です。
- Sage Therapeutics IncのEBIT marginは-458.30%です。
- Bluebird bio IncのEBIT marginは-457.81%です。
- Fiduciary/Claymore Infrastructure FundのEBIT marginは-457.51%です。
- Canuc ResourcesのEBIT marginは-452.53%です。
- Sensyne Health plcのEBIT marginは-450.76%です。
- Iconic Labs PlcのEBIT marginは-444.87%です。